PAR3 (1-6) amide (human) (trifluoroacetate salt) (Synonyms: Proteinase-Activated Receptor 3, TFRGAP-NH2) |
رقم الكتالوجGC45541 |
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
PAR3 (1-6) amide is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) and PAR2 that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) amide activates PAR1 and PAR2 in Jurkat and HEK cells, inducing calcium accumulation in Jurkat cells, which is reduced following desensitization with the PAR1- and PAR2-selective peptide agonist SFLLR-NH2.1 It decreases the expression of CDC42 in wild-type, but not PAR3 knockdown, PANC-1 cells and reduces invasion of PANC-1 cells.2
References
1. Hansen, K.K., Saifeddine, M., and Hollenberg, M.D. Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells. Immunology 112(2), 183-190 (2004).
2. Segal, L., Katz, L.S., Lupu-Meiri, M., et al. Proteinase-activated receptors differentially modulate in vitro invasion of human pancreatic adenocarcinoma PANC-1 cells in correlation with changes in the expression of CDC42 protein. Pancreas 43(1), 103-108 (2014).
Cas No. | SDF | ||
المرادفات | Proteinase-Activated Receptor 3, TFRGAP-NH2 | ||
Canonical SMILES | O=C(O)C(F)(F)F.NC([C@@H]1CCCN1C([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@@]([C@@H](C)O)([H])N[H])=O)CC2=CC=CC=C2)=O)=O)=O)C)=O)=O | ||
Formula | C29H46N10O7.XCF3COOH | M.Wt | 646.7 |
الذوبان | Water: 1 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.5463 mL | 7.7316 mL | 15.4631 mL |
5 mM | 0.3093 mL | 1.5463 mL | 3.0926 mL |
10 mM | 0.1546 mL | 0.7732 mL | 1.5463 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 21 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *